Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

Role of TGF-β in Self-Peptide Regulation of Autoimmunity.

Singh B, Krawetz MD, De Lima RM, Mukherjee R, Chaturvedi P, Lee-Chan E, Leiter EH, Summers KL.

Arch Immunol Ther Exp (Warsz). 2018 Feb;66(1):11-19. doi: 10.1007/s00005-017-0482-6. Epub 2017 Jul 21. Review.

PMID:
28733878
2.

The Presence and Preferential Activation of Regulatory T Cells Diminish Adoptive Transfer of Autoimmune Diabetes by Polyclonal Nonobese Diabetic (NOD) T Cell Effectors into NSG versus NOD-scid Mice.

Presa M, Chen YG, Grier AE, Leiter EH, Brehm MA, Greiner DL, Shultz LD, Serreze DV.

J Immunol. 2015 Oct 1;195(7):3011-9. doi: 10.4049/jimmunol.1402446. Epub 2015 Aug 17.

3.

Genetic Analysis of Substrain Divergence in Non-Obese Diabetic (NOD) Mice.

Simecek P, Churchill GA, Yang H, Rowe LB, Herberg L, Serreze DV, Leiter EH.

G3 (Bethesda). 2015 Mar 3;5(5):771-5. doi: 10.1534/g3.115.017046.

4.

Genetic and Pharmacologic Models for Type 1 Diabetes.

Leiter EH, Schile A.

Curr Protoc Mouse Biol. 2013 Mar 1;3(1):9-19.

5.

Comparison of Two New Mouse Models of Polygenic Type 2 Diabetes at the Jackson Laboratory, NONcNZO10Lt/J and TALLYHO/JngJ.

Leiter EH, Strobel M, O'Neill A, Schultz D, Schile A, Reifsnyder PC.

J Diabetes Res. 2013;2013:165327. doi: 10.1155/2013/165327. Epub 2013 Apr 8.

6.

Testing the role of P2X7 receptors in the development of type 1 diabetes in nonobese diabetic mice.

Chen YG, Scheuplein F, Driver JP, Hewes AA, Reifsnyder PC, Leiter EH, Serreze DV.

J Immunol. 2011 Apr 1;186(7):4278-84. doi: 10.4049/jimmunol.1003733. Epub 2011 Feb 25.

7.

mt-Nd2(a) Modifies resistance against autoimmune type 1 diabetes in NOD mice at the level of the pancreatic β-cell.

Chen J, Gusdon AM, Piganelli J, Leiter EH, Mathews CE.

Diabetes. 2011 Jan;60(1):355-9. doi: 10.2337/db10-1241. Epub 2010 Oct 27.

8.

Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease.

Jurisic G, Sundberg JP, Bleich A, Leiter EH, Broman KW, Buechler G, Alley L, Vestweber D, Detmar M.

Genes Immun. 2010 Apr;11(3):219-31. doi: 10.1038/gene.2010.4. Epub 2010 Mar 11.

9.

Diet-induced obesity in two C57BL/6 substrains with intact or mutant nicotinamide nucleotide transhydrogenase (Nnt) gene.

Nicholson A, Reifsnyder PC, Malcolm RD, Lucas CA, MacGregor GR, Zhang W, Leiter EH.

Obesity (Silver Spring). 2010 Oct;18(10):1902-5. doi: 10.1038/oby.2009.477. Epub 2010 Jan 7.

10.

Cdcs1 a major colitis susceptibility locus in mice; subcongenic analysis reveals genetic complexity.

Bleich A, Büchler G, Beckwith J, Petell LM, Affourtit JP, King BL, Shaffer DJ, Roopenian DC, Hedrich HJ, Sundberg JP, Leiter EH.

Inflamm Bowel Dis. 2010 May;16(5):765-75. doi: 10.1002/ibd.21146.

11.

Animal models of diabetic uropathy.

Daneshgari F, Leiter EH, Liu G, Reeder J.

J Urol. 2009 Dec;182(6 Suppl):S8-13. doi: 10.1016/j.juro.2009.07.084. Review.

12.

Mouse models of diabetic nephropathy.

Brosius FC 3rd, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M, Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K, Takahashi N, Takahashi T; Animal Models of Diabetic Complications Consortium.

J Am Soc Nephrol. 2009 Dec;20(12):2503-12. doi: 10.1681/ASN.2009070721. Epub 2009 Sep 3. Review.

13.

Selecting the "right" mouse model for metabolic syndrome and type 2 diabetes research.

Leiter EH.

Methods Mol Biol. 2009;560:1-17. doi: 10.1007/978-1-59745-448-3_1.

PMID:
19504239
14.

Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene.

Su Z, Ishimori N, Chen Y, Leiter EH, Churchill GA, Paigen B, Stylianou IM.

J Lipid Res. 2009 Oct;50(10):2083-94. doi: 10.1194/jlr.M900076-JLR200. Epub 2009 May 12.

15.

Type 1 diabetes genes in rats: few or many?

Leiter EH.

Diabetes. 2009 Apr;58(4):796-7. doi: 10.2337/db08-1811. No abstract available.

16.

NOD x 129.H2(g7) backcross delineates 129S1/SvImJ-derived genomic regions modulating type 1 diabetes development in mice.

Leiter EH, Reifsnyder PC, Wallace R, Li R, King B, Churchill GC.

Diabetes. 2009 Jul;58(7):1700-3. doi: 10.2337/db09-0120. Epub 2009 Mar 31.

17.

Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation.

Reifsnyder P, Schott W, Pomerleau D, Lessard MD, Soper BW, Leiter EH.

Novartis Found Symp. 2008;292:32-46; discussion 46-9, 122-9, 202-3.

PMID:
19203091
18.

Commonalities of genetic resistance to spontaneous autoimmune and free radical--mediated diabetes.

Chen J, Lu Y, Lee CH, Li R, Leiter EH, Mathews CE.

Free Radic Biol Med. 2008 Nov 1;45(9):1263-70. doi: 10.1016/j.freeradbiomed.2008.07.020. Epub 2008 Jul 31.

19.

The NOD mouse: a model for insulin-dependent diabetes mellitus.

Leiter EH.

Curr Protoc Immunol. 2001 May;Chapter 15:Unit 15.9. doi: 10.1002/0471142735.im1509s24.

PMID:
18432739
20.
21.

Unexpected functional consequences of xenogeneic transgene expression in beta-cells of NOD mice.

Leiter EH, Reifsnyder P, Driver J, Kamdar S, Choisy-Rossi C, Serreze DV, Hara M, Chervonsky A.

Diabetes Obes Metab. 2007 Nov;9 Suppl 2:14-22.

PMID:
17919174
22.

Adipokine and insulin profiles distinguish diabetogenic and non-diabetogenic obesities in mice.

Leiter EH, Reifsnyder PC, Xiao Q, Mistry J.

Obesity (Silver Spring). 2007 Aug;15(8):1961-8.

23.

Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes.

Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, Higashimori T, Zhang Z, Jung DY, Ola MS, Lanoue KF, Leiter EH, Kim JK.

Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E327-36.

24.

Leptin in autoimmunity: many questions, some answers.

Matarese G, Leiter EH, La Cava A.

Tissue Antigens. 2007 Aug;70(2):87-95. Review.

PMID:
17610413
25.

A polymorphism in New Zealand inbred mouse strains that inactivates phosphatidylcholine transfer protein.

Pan HJ, Agate DS, King BL, Wu MK, Roderick SL, Leiter EH, Cohen DE.

FEBS Lett. 2006 Oct 30;580(25):5953-8. Epub 2006 Oct 6.

26.

CD38 is required for the peripheral survival of immunotolerogenic CD4+ invariant NK T cells in nonobese diabetic mice.

Chen YG, Chen J, Osborne MA, Chapman HD, Besra GS, Porcelli SA, Leiter EH, Wilson SB, Serreze DV.

J Immunol. 2006 Sep 1;177(5):2939-47.

27.

Resistance of C57BL/6 mice to amoebiasis is mediated by nonhemopoietic cells but requires hemopoietic IL-10 production.

Hamano S, Asgharpour A, Stroup SE, Wynn TA, Leiter EH, Houpt E.

J Immunol. 2006 Jul 15;177(2):1208-13.

28.

The diabetes-prone NZO/Hl strain. Proliferation capacity of beta cells in hyperinsulinemia and hyperglycemia.

Lange C, Jeruschke K, Herberg L, Leiter EH, Junger E.

Arch Physiol Biochem. 2006 Feb;112(1):49-58.

PMID:
16754203
29.

Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.

Pan HJ, Lin Y, Chen YE, Vance DE, Leiter EH.

Vascul Pharmacol. 2006 Jul;45(1):65-71. Epub 2006 Jun 5.

PMID:
16750656
30.

Targeted disruption of CD38 accelerates autoimmune diabetes in NOD/Lt mice by enhancing autoimmunity in an ADP-ribosyltransferase 2-dependent fashion.

Chen J, Chen YG, Reifsnyder PC, Schott WH, Lee CH, Osborne M, Scheuplein F, Haag F, Koch-Nolte F, Serreze DV, Leiter EH.

J Immunol. 2006 Apr 15;176(8):4590-9.

31.

Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis.

Lee CH, Chen YG, Chen J, Reifsnyder PC, Serreze DV, Clare-Salzler M, Rodriguez M, Wasserfall C, Atkinson MA, Leiter EH.

Diabetes. 2006 Jan;55(1):171-8.

32.
33.

Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens.

Beckwith J, Cong Y, Sundberg JP, Elson CO, Leiter EH.

Gastroenterology. 2005 Nov;129(5):1473-84.

PMID:
16285949
34.

"Agouti NOD": identification of a CBA-derived Idd locus on Chromosome 7 and its use for chimera production with NOD embryonic stem cells.

Chen J, Reifsnyder PC, Scheuplein F, Schott WH, Mileikovsky M, Soodeen-Karamath S, Nagy A, Dosch MH, Ellis J, Koch-Nolte F, Leiter EH.

Mamm Genome. 2005 Oct;16(10):775-83. Epub 2005 Oct 29.

PMID:
16261419
35.

Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.

Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, Mistry J.

Endocrinology. 2006 Feb;147(2):919-26. Epub 2005 Oct 27.

PMID:
16254032
36.

Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: I. Pathophysiological analysis.

Lee CH, Reifsnyder PC, Naggert JK, Wasserfall C, Atkinson MA, Chen J, Leiter EH.

Diabetes. 2005 Sep;54(9):2525-32.

37.

Conditioning the genome identifies additional diabetes resistance loci in Type I diabetes resistant NOR/Lt mice.

Reifsnyder PC, Li R, Silveira PA, Churchill G, Serreze DV, Leiter EH.

Genes Immun. 2005 Sep;6(6):528-38. Erratum in: Genes Immun. 2006 Mar;7(2):184.

PMID:
16015371
38.

Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction.

Mathews CE, Suarez-Pinzon WL, Baust JJ, Strynadka K, Leiter EH, Rabinovitch A.

J Immunol. 2005 Jul 15;175(2):1248-56.

39.

Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes.

Pan HJ, Reifsnyder P, Vance DE, Xiao Q, Leiter EH.

Diabetes. 2005 Jun;54(6):1854-62.

41.

Nonobese diabetic mice and the genetics of diabetes susceptibility.

Leiter EH.

Curr Diab Rep. 2005 Apr;5(2):141-8. Review.

PMID:
15794919
42.

CD38 controls ADP-ribosyltransferase-2-catalyzed ADP-ribosylation of T cell surface proteins.

Krebs C, Adriouch S, Braasch F, Koestner W, Leiter EH, Seman M, Lund FE, Oppenheimer N, Haag F, Koch-Nolte F.

J Immunol. 2005 Mar 15;174(6):3298-305.

43.

Proteasome inhibition alters glucose-stimulated (pro)insulin secretion and turnover in pancreatic {beta}-cells.

Kitiphongspattana K, Mathews CE, Leiter EH, Gaskins HR.

J Biol Chem. 2005 Apr 22;280(16):15727-34. Epub 2005 Feb 9.

44.

P2X7 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide.

Kawamura H, Aswad F, Minagawa M, Malone K, Kaslow H, Koch-Nolte F, Schott WH, Leiter EH, Dennert G.

J Immunol. 2005 Feb 15;174(4):1971-9.

45.

mt-Nd2 Allele of the ALR/Lt mouse confers resistance against both chemically induced and autoimmune diabetes.

Mathews CE, Leiter EH, Spirina O, Bykhovskaya Y, Gusdon AM, Ringquist S, Fischel-Ghodsian N.

Diabetologia. 2005 Feb;48(2):261-7. Epub 2005 Feb 4.

PMID:
15692809
46.

Refined histopathologic scoring system improves power to detect colitis QTL in mice.

Bleich A, Mähler M, Most C, Leiter EH, Liebler-Tenorio E, Elson CO, Hedrich HJ, Schlegelberger B, Sundberg JP.

Mamm Genome. 2004 Nov;15(11):865-71.

PMID:
15672590
47.

Anti-insulin receptor autoantibodies are not required for type 2 diabetes pathogenesis in NZL/Lt mice, a New Zealand obese (NZO)-derived mouse strain.

McInerney MF, Najjar SM, Brickley D, Lutzke M, Abou-Rjaily GA, Reifsnyder P, Haskell BD, Flurkey K, Zhang YJ, Pietropaolo SL, Pietropaolo M, Byers JP, Leiter EH.

Exp Diabesity Res. 2004 Jul-Sep;5(3):177-85.

48.

Animal models have little to teach us about type 1 diabetes: 2. In opposition to this proposal.

Leiter EH, von Herrath M.

Diabetologia. 2004 Oct;47(10):1657-60. Epub 2004 Oct 19. Review. No abstract available.

PMID:
15502929
49.

Absence of a reductase, NCB5OR, causes insulin-deficient diabetes.

Xie J, Zhu H, Larade K, Ladoux A, Seguritan A, Chu M, Ito S, Bronson RT, Leiter EH, Zhang CY, Rosen ED, Bunn HF.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10750-5. Epub 2004 Jul 9.

50.

Contributions of dysregulated energy metabolism to type 2 diabetes development in NZO/H1Lt mice with polygenic obesity.

Koza RA, Flurkey K, Graunke DM, Braun C, Pan HJ, Reifsnyder PC, Kozak LP, Leiter EH.

Metabolism. 2004 Jun;53(6):799-808.

PMID:
15164332

Supplemental Content

Loading ...
Support Center